Capricorn Technologies’ influenza viral vector activities are supported by granted intellectual property and proprietary manufacturing technologies. Ownership and licensing relationships differ among the underlying assets.
UniFluVec — Influenza Viral Vector Technology
The UniFluVec core technology is protected by an international patent family originating from WO 2017/078577, covering genetically attenuated influenza A viral vectors and their vaccine applications. Corresponding patents have been granted in multiple important jurisdictions, including the United States, China, Japan, South Korea, Canada, and Australia. US Patent No. 10,392,604 B2 is a representative granted member of this family. According to Capricorn’s BARDA materials, Capricorn holds an exclusive worldwide license to the underlying technology. The legal status and territorial coverage of the patent family and license should be confirmed before publication.
AEX-1 — Proprietary Cell Substrate
AEX-1 is the subject of international patent application WO 2026/195656 A1, “Modified Vero Cell Line for Virus Propagation,” filed by NuCell GmbH, a subsidiary of Capricorn Technologies GmbH. The published PCT application has a priority date of 17 March 2025 and publication date of 24 September 2026. It describes AEX-1 (DSM ACC3381) and its potential use in virus propagation and vaccine manufacturing.
Key Patent Publications
UniFluVec international family: https://patents.google.com/patent/WO2017078577A2/en
Representative US grant: https://patents.google.com/patent/US10392604B2/en
AEX-1 international publication: https://patents.google.com/patent/WO2026195656A1/en